- Global Pharma News & Resources

Journal Article Cites AlbuSorb™ for Analysis of High-fat Diet–induced Metabolic Changes

MONMOUTH JUNCTION, NJ, March 19, 2021 -- Biotech Support Group reports on a recent journal article using AlbuSorb™ to determine the amount of circulating apoCIII in plasma, a key regulator of lipid metabolism.


The citation is:

Valladolid-Acebes, Ismael, et al. "Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements.Science Advances 7.11 (2021): eabc2931.


Increased levels of apolipoprotein CIII (apoCIII), result in obesity-related metabolic derangements. Using mice, the researchers investigated mechanistically whether lowering or preventing high-fat diet (HFD)– induced increase in apoCIII, protects against the detrimental metabolic consequences. For Western blotting determination of circulating apoCIII, the article states, “plasma was albumin depleted using AlbuSorb according to the manufacturer’s protocol (Biotech Support Group LLC) and resuspended in 0.1% (v/v) trifluoroacetic acid.” The research concludes that lowering apoCIII protects against and reverses the HFD-induced metabolic phenotype by promoting physiological insulin sensitivity.


“This reference shows that AlbuSorb™ is very selective for depleting albumin and enriching the apolipoprotein fraction including apoCIII. Without the associated interference from Albumin, Western blot analysis becomes much more defined. Also, as our bead technology does not rely on immuno-affinity, it works for all species; mice in this example.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: AlbuSorb™ at

For more information on our complete line of Albumin & IgG Removal, visit:


About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to

Matthew Kuruc

Editor Details

  • Name:
    • Matthew Kuruc
Last Updated: 26-Mar-2021